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• [D-Ser2]palmitoyl-paddlefish glucagon is resistant to degradation by plasma 
peptidases and DPP-IV 
• The peptide enhanced in vitro insulin secretion from BRIN-BD11 clonal β-cells and 
mouse islets 
• The peptide augmented β-cell proliferation and reduced cytokine-mediated apoptosis 
• The peptide improved glucose tolerance in lean mice when injected up to 4 h before a 
glucose load. 
• Twice daily administration to high-fat fed mice over 21 days reduced food intake and 
body weight 














This study has examined the in vitro and in vivo anti-diabetic properties of the peptidase-
resistant analogues [D-Ser2]palmitoyl-paddlefish glucagon and [D-Ser2]palmitoyl-lamprey 
glucagon. The peptides stimulated insulin release from BRIN-BD11 clonal β-cells and 
isolated mouse pancreatic islets and also enhanced cAMP production in cells transfected with 
the human GLP-1 receptor and with the human glucagon receptor. The insulinotropic actions 
of the peptides were attenuated in INS-1 cells lacking GLP-1 and glucagon receptors. [D-
Ser2]palmitoyl-paddlefish glucagon stimulated proliferation of BRIN-BD11 cells and 
protected against cytokine-mediated apoptosis as effectively as GLP-1. The analogue was 
more effective than the native peptide or the lamprey glucagon analogue in acutely lowering 
blood glucose and elevating plasma insulin in lean mice even when administered up to 4 h 
before a glucose load. Twice daily administration of [D-Ser2]palmitoyl-paddlefish glucagon 
to high-fat fed mice over 21 days reduced food intake, body weight, non-fasting blood 
glucose and plasma insulin concentrations, as well as significantly improving glucose 
tolerance and insulin resistance and decreasing α-cell area and pancreatic insulin content. 
Islet expression of the Gcgr, Glp1r, Gipr and Slc2a2 (GLUT-2) genes significantly increased. 
These data demonstrate that long-acting peptide [D-Ser2]palmitoyl-paddlefish glucagon 
exerts beneficial metabolic properties in diabetic mice via Ggcr- and Glp1r-activated 
pathways and so shows potential as a template for further  development into an agent for 
treatment of patients with obesity-related Type 2 diabetes.  
 









Glucagon-like peptide-1 (GLP-1) stimulates insulin release as well as supressing both 
glucagon release and appetite and promoting proliferation of ß-cells (Hare et al., 2010; Dailey 
and Moran, 2013; Drucker, 2018). Consequently, the use of GLP-1 receptor (GLP1R) 
agonists in the treatment of patients with Type 2 diabetes mellitus (T2DM) is well 
established. Several long-acting chemically modified analogues, such as liraglutide, 
albiglutide, and lixisenatide, have been developed and are in use in clinical practice (Bailey, 
2018). The idea that glucagon, a potent stimulator of glycogenolysis and gluconeogenesis, or 
its derivatives may find application in T2DM therapy appears at first sight to be paradoxical. 
However, administration of glucagon promotes weight loss, an important factor in reversing 
insulin resistance, by increasing energy expenditure and lipid catabolism suggesting a 
possible therapeutic role in the management of obesity-related T2DM (Scott and Bloom, 
2018; Al-Massadi et al., 2019).  
The last decade has seen the development of a new approach to incretin-based therapy 
by design of a range of unimolecular co-agonists of GLP1R and the glucagon receptor 
(GCGR) that are capable of activating different signalling pathways (Pocai et al., 2009; Day 
et al., 2009; Henderson et al., 2016; Evers et al., 2017; Zhou et al., 2017). Such agents 
combine the insulinotropic and anorectic effects of GLP-1 with the lipolytic and thermogenic 
actions of glucagon and are effective in reducing body weight and improving glucose 
tolerance, lipid metabolism, and hepatic steatosis (Brandt et al., 2018). In addition, the 
hyperglycaemic action of glucagon restrains the insulin-mediated glucose lowering action of 
GLP-1 preventing episodes of hypoglycaemia. The naturally occurring GCCR/GLP1R dual- 
agonist peptide, oxyntomodulin stimulates insulin release and improves glucose tolerance 
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when administered to mice and, at pharmacological doses, will inhibit appetite and food 
intake (Lynch et al., 2014; Holst et al., 2018). In the past, clinical application of glucagon has 
largely been confined to the emergency management of insulin-induced hypoglycaemia 
(Hawkes et al., 2019) but, with the availability of long-acting, dual-agonist peptides based 
upon the primary structure of glucagon and either GLP-1 or glucose-dependent insulinotropic 
peptide (GIP), this situation is likely to change. 
Glucagon isolated from the dogfish Scyliorhinus canicula (Elasmobranchii) targets 
both the GLP-1 and glucagon receptors in vitro (O’Harte et al., 2016a) and shows strong 
anti-hyperglycaemic and insulinotropic effects in mice (O’Harte et al., 2016b). A more 
recent study has shown that the potent glucose-lowering and insulinotropic actions of 
glucagons from the phylogenetically ancient sea lamprey Petromyzon marinus 
(Petromyzontiformes) and the North American paddlefish Polyodon spathula 
(Acipenseriformes) in mice are also mediated by activation of both Glp1r and Gcgr 
(Graham et al., 2018a). Lamprey and paddlefish glucagons are rapidly cleaved by plasma 
peptidases and dipeptidyl peptidase IV (DPP-IV, EC 3.4.14.5) producing inactive 
fragments (Graham et al., 2018a) thereby limiting their therapeutic potential. A successful 
strategy for producing long-acting, peptidase-resistant  anti-hyperglycaemic agents derived 
from dogfish glucagon (O’Harte et al., 2016b) and lamprey GLP-1 (Graham et al., 2020)  
involved modification of the naturally occurring peptides at position 2 by substitution of 
L-Ser by D-Ser  and attachment of a C-16 fatty acid to a lysine residue in the molecule via 
a γ-glutamyl linker. The present study has adopted this strategy to produce analogues of 
paddlefish and lamprey glucagons with increased resistance to proteolytic degradation and 









[D-Ser2,Lys30-γ-glutamyl-palmitate]-lamprey glucagon ([D-Ser2]palmitoyl-lamprey 
glucagon) and [D-Ser2,Lys30-γ-glutamyl-palmitate]-paddlefish glucagon ([D-Ser2]palmitoyl-
paddlefish glucagon) were supplied in crude form by Synpeptide Co. Ltd. (Shanghai, China). 
The peptides were purified to > 98% homogeneity by reversed-phase HPLC on a (2.2 cm x 
25 cm) Vydac 218TP1022 (C-18) column.  The concentration of acetonitrile in the eluting 
solvent was raised from 38.5% to 70 % over 60 min using a linear gradient. Absorbance was 
measured at 214 nm and the flow rate was 6 ml/min.  The molecular masses of the peptides 
were confirmed by matrix-assisted laser desorption ionization time-of-flight mass (MALDI-
TOF) spectrometry using a Voyager DE PRO instrument (Applied Biosystems, Foster City, 
USA) as previously described (Conlon et al., 2018). The primary structures and molecular 
masses of the peptides used in this study are shown in Table 1. 
 
2.2. Degradation assays 
 
Lamprey glucagon, paddlefish glucagon, human glucagon, [D-Ser2]palmitoyl-lamprey 
glucagon and [D-Ser2]palmitoyl-paddlefish glucagon (30 μg and 100 μg) were separately 
incubated in 50 mM triethanolamine buffer, pH 7.8 (390 µl) with either (a) purified porcine 
DPP-IV (5 mU; Merck Millipore) or (b) pooled plasma (10 µl) from  National Institutes of 
Health (NIH) Swiss mice for 4 h at 37 °C. Each reaction mixture was chromatographed at a 
flow rate of 1.0 ml/min on a (250 x 4.6 mm) Luna 5µ C-8 column (Phenomenex, 
Macclesfield, U.K.) using linear gradients of acetonitrile (0% to 35% from 0 min to 10 min, 
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35% to 42% from 10 min to 30 min, and 42 to 70% from 30 min to 35 min) for elution. 
Peptides were detected by measurement of absorbance at 214 nm and analysed by MALDI-
TOF mass spectrometry. % intact peptide was calculated from the peak area. 
 
2.3. In vitro insulin release studies using BRIN-BD11 cells 
 
BRIN-BD11 clonal β-cells (McClenaghan et al., 1996) were used to assess in vitro 
insulin secretory activity of peptides as previously described (Graham et al., 2018b; 2019).  
Briefly, the cells were seeded (150,000 cells/well) into 24-well plates (Nunc, Roskilde, 
Denmark) and allowed to attach overnight at 37 °C. Cells were incubated for 20 min at 37 °C 
in Krebs-Ringer Bicarbonate (KRB) buffer, pH 7.4  supplemented with 5.6 mM  glucose in 
the presence of the peptides in the concentration range (1 pM - 3 µM; n = 8). After 20 min 
incubation, the supernatant was removed from each well and stored at −20 °C prior to 
measurement of insulin concentrations by radioimmunoassay (Flatt and Bailey, 1981). 
 
2.4. Insulin release studies using isolated mouse islets 
 
Effects of the fish glucagon analogues on ex-vivo insulin secretion were assessed 
using isolated pancreatic islets from adult, male NIH Swiss mice (Harlan Ltd, Bicester, UK) 
as previously described (Ojo et al., 2016). The islets were cultured for 48 h at 37 °C in an 
atmosphere of 5% CO2 and 95% air prior to incubation with peptides (10 nM and 1µM; n = 
4) and alanine (10 mM; n = 4) for 1 h at 37˚C in KRB buffer supplemented with 16.7 mM 
glucose. Insulin release was measured by radioimmunoassay and the insulin content was 




2.5. Effects on cAMP production 
 
The effects of the peptides to stimulate cAMP production were determined using 
Chinese hamster lung (CHL) cells transfected with GLP1R (Thorens et al., 1993) and human 
embryonic kidney (HEK293) cells transfected with GCGR (Ikegami et al., 2001) as 
previously described (Graham et al., 2018a). The cells were pre-incubated for 40 min with 
KRB buffer supplemented with 0.1% (w/v) bovine serum albumin (BSA) and 1.1 mmol/l 
glucose. A test solution containing KRB buffer supplemented with 0.1% (w/v) BSA, 5.6 mM 
glucose, 200 µM 3-isobutyl-1-methylxanthine and peptides (10-8 and 10-6 M) were added to 
the cells. After incubating for 60 min, the medium was removed and cells were lysed before 
measurement of cAMP using a Parameter cAMP assay kit (R&D Systems, Abingdon, UK) 
according to the manufacturer’s recommended protocol.  
 
2.6. Insulin release studies using CRISPR/Cas9-engineered INS-1 cells 
 
The effects of the peptides to stimulate insulin release  were determined using wild-
type INS-1 832/3 rat clonal pancreatic β-cells and CRISPR/Cas9-engineered cells with  
knock-out of the glucagon receptor (Gcgr KO) (Graham et al., 2020), GLP-1 receptor (Glp1r 
KO) (Naylor et al., 2016) or GIP receptor (Gipr KO) (Naylor et al., 2016). The cells were 
cultured and incubated as described for BRIN-BD11 cells with the addition of 1 mM sodium 
pyruvate and 50 mM 2-mercaptoethanol to the medium (Graham et al., 2018b; 2019) The 
cells were incubated with 10-8 and 10-6 M  concentrations of GLP-1, glucagon, GIP, and the 
fish peptide analogues for 20 min at 37 °C in KRB buffer supplemented with 5.6 mM glucose 




2.7. Effects on proliferation of BRIN-BD11 cells 
 
To assess the effects of [D-Ser2]palmitoyl-lamprey glucagon, [D-Ser2]palmitoyl-
paddlefish glucagon, and human GLP-1 (10-8 and 10-6 M ) on proliferation, BRIN-BD11 cells 
were incubated with the peptides for 18 h at 37 °C and fixed as previously described (Khan et 
al., 2016; Graham et al., 2018a). After fixation, cells were stained with rabbit anti-Ki-67 
primary antibody and subsequently with Alexa Fluor 594 secondary antibody (Abcam. 
Cambridge, UK). Proliferation frequency was determined in a blinded fashion and expressed 
as % of total cells analyzed. Approximately 150 cells per replicate were analyzed.   
 
2.8. Effects on cytokine-induced apoptosis in BRIN-BD11 cells 
 
BRIN-BD11cells were incubated with peptides (10-8 and 10-6 M) and a cytokine 
mixture (200 U/ml tumour-necrosis factor-α, 20 U/ml interferon-γ, and 100 U/ml interleukin-
1β) for 16 h at 37 °C as previously described (Khan et al., 2016). Effects on apoptosis were 
measured using an in situ Cell Death Detection Kit (Roche Diagnostics, Burgess Hill, UK) 
for 1 h at 37 °C following the manufacturer’s recommended procedure. Slides were viewed 
using a fluorescent microscope with 488 nm filter (Olympus System Microscope, model 




  All animal experiments were carried out in accordance with the UK Animals 
(Scientific Procedures) Act 1986 and EU Directive 2010/63EU for animal experiments and 
approved by Ulster University Animal Ethics Review Committee (ref. UOA3/B/115).  All 
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necessary steps were taken to prevent any potential animal suffering. Mice were maintained 
in environmentally controlled rooms (12h:12 h light/darkness cycle, 22 ± 2 oC) with free 
access to food and water. Acute in vivo insulin-release studies were carried out using 8 - 10 
week-old male NIH Swiss mice maintained on a standard rodent diet (10% fat, 30% protein, 
60% carbohydrate: total energy 12.99 kJ/g; Trouw Nutrition, Northwich, UK) and water. 
Food intake studies were carried out in 8 - 10 week-old male NIH Swiss mice as previously 
described (O’Harte et al., 2017).  
         Longer term effects of  peptide treatment were investigated  using 8-12 week-old male 
NIH Swiss mice maintained on high-fat chow (45% fat, 20% protein, and 35% carbohydrate 
(total energy, 26.15 KJ/g; Special Diets Service, Essex, UK) with free access to water for 3 
months prior to the start of experiments in order to produce obesity, glucose intolerance, and 
insulin resistance. Body weight, blood glucose, and plasma insulin concentrations were 
monitored at regular intervals. The animals were allocated into groups with matching average 
body weights and blood glucose levels prior to starting the experiment. Mice remained on a 
high-fat diet for the duration of the study. 
 
2.10. Effects of peptide administration on glucose tolerance, insulin release and food intake 
in lean mice 
 
Blood glucose and plasma insulin concentrations were measured after intraperitoneal 
(i.p.) injection of glucose (18 mmol/kg body weight) either alone or together with peptides 
(25 nmol/kg) in overnight-fasted lean mice as previously described (Owolabi et al., 2016a). 
In a separate series of experiments, blood glucose and plasma insulin were measured after i.p. 
injection of glucose (18 mmol/kg) either 2 h or 4 h after ip administration of saline, lamprey 
glucagon, paddlefish glucagon, [D-Ser2]palmitoyl-lamprey glucagon or [D-Ser2]palmitoyl-
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paddlefish glucagon (25 nmol/kg). For food intake studies, mice (21 h fasted) received ip 
injections of either 0.9% (w/v) NaCl solution or peptides (25nmol/kg) and were allowed free 
access to food pellets. The weight of food consumed was recorded at 30 min intervals up to 
180 min. Consumption of water was not restricted. 
 
2.11. Effects of twice daily peptide administration on insulin resistance in high-fat-fed mice 
 
         High-fat fed mice received twice-daily ip injections of 0.9 % saline solution for three 
days before administration of either 0.9% saline (control) or peptides (25 nmol/kg) twice 
daily (09:30 and 17:00 h) over 21 days.  Non-fasting blood glucose, cumulative food and 
water intake, body weight, and plasma insulin concentrations were monitored at 3-day 
intervals before daily injection of test peptides. The peptide treatment groups (n = 8 for all 
groups) were as follows: Group 1: 0.9% saline; Group 2: liraglutide, (25 nmol/kg); Group 3: 
[D-Ser2]palmitoyl-paddlefish glucagon (25 nmol/kg). Oral and i.p. glucose tolerance (18 
mmol/kg) and insulin sensitivity (25 U/kg; i.p.) tests were performed after 21 days of 
treatment as previously described (Owolabi et al., 2016b). HOMA-β and HOMA-IR were 
calculated using standard formula as described (Wallace et al., 2004).  Mice were killed at the 
end of the treatment period to obtain pancreata and terminal blood. Bone mineral density and 
body tissue composition were measured using DEXA scanning (Owolabi et al., 2016b).  
2.12.  Biochemical analyses  
         Blood glucose concentration was measured using an Ascenacia Counter Blood Glucose 
Meter (Bayer, Newbury, UK). Blood samples were collected in fluoride/heparin 
microcentrifuge tubes (Sarstedt, Numbrecht, Germany) and centrifuged for 30 s at 13,000 × 
g. Terminal non-fasted blood was collected for measurement of plasma glucagon 
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concentrations (Glucagon Chemiluminescent Assay, Millipore Corporation, Germany). 
Plasma amylase (Abcam, ab102523) and alanine aminotransferase (ALT Reagent, Randox, 
UK) activities were measured following the manufacturer’s instructions. Plasma cholesterol 
levels were measured using an automated analyser (I-Lab 650 Integrated Chemistry System, 
Instrumentation Laboratory, Warrington, UK). LDL-cholesterol concentrations were 
calculated using the Friedewald equation as described (Johnson et al., 1997). Pancreatic 
tissues were homogenised and extracted using buffer containing 20 mM Tris HCl (pH 7.5), 
150 mM NaCl, 1 mM EDTA, 1 mM EGTA and 0.5% Triton X 100 and stored at -800 C. 
Protein concentrations were determined using Bradford reagent (Sigma, Dorset, UK). 
 
2.13. Insulin release studies using islets from 21-day treated high-fat fed animals   
 
           Pancreatic islets were isolated as previously described (Ojo et al., 2016). Following a 
60-min pre-incubation with 1.4 mM glucose, the islets were incubated with KRB buffer (500 
µl) supplemented with 0.5% BSA and 16.7 mM glucose and the test agents (10 mM alanine, 
20 mM KCl, 10 mM arginine, 1 µM human GLP-1 and 1µM human GIP). Tubes were 
incubated for 60 min at 37◦C followed by centrifugation at 800 x g for 5 min.  The 
supernatants were stored at -20 ◦C for determination of insulin release by radioimmunoassay. 
The remaining islets were stored at -70◦C for the gene expression studies. 
 
2.14. Tissue processing for histological analyses  
 
         Pancreatic tissues from each group of mice were fixed and processed as previously 
described (Vasu et al 2014). The following primary antibodies were used as appropriate: 
mouse monoclonal anti-insulin antibody (ab6995, 1:400; Abcam, Cambridge, UK) and 
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guinea-pig anti-glucagon antibody (PCA2/4, 1:50; raised in-house). The following secondary 
antibodies were used as appropriate: Alexa Fluor 488 goat anti-guinea pig IgG (1:400) and 
Alexa Fluor 594 goat anti-mouse IgG (1:400). The slides were viewed under a fluorescent 
microscope (Olympus model BX51) with the DP70 camera adapter system. Islet parameters 
(islet number, islet area, β-cell area, α-cell area and islet size distribution) were determined 
using Cell^F image analysis software (Olympus Soft Imaging Solutions GmbH, Münster, 
Germany).  
 
2.15. Islet gene expression 
 
         mRNA was extracted from collagenase-digested islets using TriPure Isolation Reagent 
(Roche, Burgess Hill , UK) (1ml/0.5 g of cells) following the manufacturer’s instructions and 
converted to cDNA using SuperScript™ II Reverse Transcriptase (Invitrogen Life 
Technologies, Carlsbad, CA, USA) (Vasu et al. 2013). Real-time polymerase chain reaction 
(PCR) was performed using a MJ Mini Personal Thermal Cycler (Bio-Rad Laboratories Ltd., 
Watford, U.K.). PCR reaction mixture (containing 4.5 µl of QuantiFast SYBR green PCR 
mix (Qiagen, Venlo, Netherlands), 1 µl of forward and 1 µl reverse primers, 3 µl of cDNA 
and 1 µl of nuclease-free water) was added to the PCR tube strips. DNA denaturation was 
performed at 95°C for 5 min followed by a 40-cycle cDNA amplification with final 
denaturation at 95°C for 30 s, annealing at 58 °C for 30 s and elongation at 72°C for 30 s. 
SYBR Green fluorescence was recorded after each cycle. Data were normalized to β-actin 
(Actb) gene expression and analysed using the ΔΔCt method as previously described 





2.16.  Statistical analysis 
 
          Data were compared using one-way ANOVA with Bonferroni post-hoc test and 
unpaired Student’s t-test (non-parametric, with two-tailed P values and 95% confidence 
interval) as appropriate (GraphPad PRISM Version 5.0 San Diego, California).  Area under 
the curve (AUC) analysis was performed using the trapezoidal rule with baseline correction. 
Data are presented as mean ± S.E.M. 
 
3.  Results 
 
3.1. Degradation studies 
 
Both [D-Ser2]palmitoyl-lamprey glucagon and [D-Ser2]palmitoyl-paddlefish glucagon 
were stable to degradation after 4 h incubation with either DPP-IV or mouse  plasma (Fig. 1A 
and Table 2). In contrast, under the same conditions the underivatized lamprey and paddlefish 
glucagons and human glucagon were susceptible to rapid proteolytic cleavage by DPP-IV at 
the Ser2 residue site to generate inactive metabolites. 
3.2. In vitro insulin-releasing activities of the fish glucagon analogues 
Incubation of [D-Ser2]palmitoyl-lamprey glucagon and [D-Ser2]palmitoyl-paddlefish 
glucagon with BRIN-BD11 cells increased the rate of insulin release in a concentration-
dependent manner (Figs.1B and 1C). The rate of insulin release stimulated by the lamprey 
glucagon analogue at 3 µM concentration was significantly (P < 0.05) less than that the 
parent peptide but the threshold concentration was lower (0.3 nM vs 3 nM) (Table 3). The 
effect of the paddlefish glucagon analogue at 3 µM concentration was comparable to that of 
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the underivatized peptide and human GLP-1 and the threshold concentration was 10-fold 
lower (0.01 nM vs 0.1 nM). Incubation with [D-Ser2]palmitoyl-paddlefish glucagon (10 nM 
and 1 µM) increased the rate of insulin release from isolated mouse islets by amounts that  
were comparable to those produced by human GLP-1 (Fig. 1D). The small increases in rate 
produced by incubation of islets with the lamprey analogue (10 nM and 1 µM) were not 
significant. 
 
3.3.   Effects of the fish glucagon analogues on cAMP production 
 
Incubation of CHL cells expressing GLP1R with [D-Ser2]palmitoyl-lamprey glucagon 
resulted in significantly increased cAMP production at both 10 nM and 1 µM concentration 
compared with control. However, the effect at 10 nM was significantly less than that 
produced by human GLP-1 (Fig. 1E). The stimulatory effect of [D-Ser2]palmitoyl-paddlefish 
glucagon was comparable to that of human GLP-1 at both 10 nM and 1 µM concentrations 
(Fig. 1E). Both analogues at concentrations of 10 nM and 1 µM stimulated cAMP production 
in HEK293 cells transfected with the human glucagon receptor but the magnitude of 
responses produced by [D-Ser2]palmitoyl-lamprey glucagon were appreciably less than those 
produced by human GLP-1 (Fig. 1F). 
 
3.4. Insulin release studies using CRISPR/Cas9-engineered INS-1 cells 
 
Incubations with [D-Ser2]palmitoyl-lamprey glucagon and [D-Ser2]palmitoyl-
paddlefish glucagon at both 10 nM and 1 μM concentrations significantly increased the rate 
of insulin release from wild-type INS-1 cells (Fig. 2A). Incubation of the analogues with 
Glp1r KO cells and Gcgr KO cells attenuated the stimulatory effects on insulin secretion 
compared to wild-type INS-1 cells (Fig. 2B and 2C). In contrast, incubation of the analogues 
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with Gipr KO cells produced a stimulation in the rate of insulin release that was not 
significantly different from the response in wild-type cells (Fig. 2D) indicating the actions of 
the analogues are not mediated through activation of the GIP receptor. 
 
3.5. Effects on proliferation and survival of BRIN-BD11 cells 
 
Incubations with human GLP-1 and the fish glucagon analogues (10 nM and 10 µM) 
significantly (P < 0.001) augmented the proliferation of BRIN-BD11cells compared with 
incubations with media alone (Fig. 2E). In the second series of experiments, incubation, of 
the cells with a mixture of proinflammatory cytokines significantly (P < 0.001) increased the 
number of cells undergoing apoptosis. [D-Ser2]palmitoyl-lamprey glucagon (10 nM and 10 
µM) was equally as effective as GLP-1 in protecting BRIN-BD11cells against cytokine-
induced DNA damage but the lamprey analogue was inactive (Fig. 2F). 
 
3.6. Effects on glucose tolerance in overnight fasted lean mice 
 
Administration of [D-Ser2]palmitoyl-paddlefish glucagon along with a 18 mmol/kg 
i.p. glucose load significantly (P < 0.01 - P < 0.001) reduced blood glucose concentrations at 
15, 30 and 60 min (Fig. 3A) and also the integrated glucose response (Fig. 3C) compared 
with the effect of administration of glucose alone. The effects of the paddlefish glucagon 
analogue were not significantly different from those of human GLP-1 and exendin-4 at each 
time point.  These observations were consistent with a significantly (P < 0.01 - P < 0.001) 
increased insulin secretory response to the paddlefish glucagon analogue at 15, 30 and 60 min 
(Fig. 3B) and a greater integrated response (Fig. 3D) compared with i.p. injection of glucose 
alone. Plasma insulin concentrations after administration of the paddlefish analogue and 
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exendin-4 were significantly (P < 0.001) greater at 60 min post-injection compared with 
those following GLP-1 but the integrated responses were similar.  In marked contrast, [D-
Ser2]-palmitoyl lamprey glucagon (25 nmol/kg) had lost the beneficial glucose-lowering 
properties of the parent peptide and administration failed to elicit any significant effects on 
glucose (Fig. 3A) or insulin (Fig. 3B) concentrations.  
When administrated 2 h (Supplementary Fig, 1) and 4 h (Supplementary Fig. 2) prior 
to the glucose load, [D-Ser2]palmitoyl-paddlefish glucagon and exendin-4 significantly 
reduced circulating glucose concentrations and elevated insulin concentrations at each time 
point compared with glucose injection only whereas, as expected, the glucose-lowering and 
insulin-releasing actions of GLP-1 had disappeared. The integrated glucose responses to the 
paddlefish glucose analogue and exendin-4, administered 2 h (Supplementary Fig, 1) and 4 h 
(Figs. 3E and 3F) before the glucose load were significantly (P < 0.001) less and 
corresponding integrated insulin responses significantly (P < 0.001) greater than those 
following GLP-1 injection.   
 
3.7. Effects of fish glucagon peptides on food intake in lean mice  
 
Administration of [D-Ser2]palmitoyl-paddlefish glucagon at a dose of 25 nmol/kg 
body weight to overnight fasted animals significantly (P < 0.05) suppressed feeding at all 
time points up to 180 min  (Supplementary Fig. 3B).  The appetite suppressive effects of 
paddlefish glucagon and its analogue were comparable to the effects of exendin-4. In 
contrast, ip administration of the lamprey glucagon analogue resulted in a small reduction of 




3.8 Effects of 21-day administration [D-Ser2]-palmitoyl paddlefish glucagon on food intake, 
body weight, and circulating glucose and insulin concentrations in high-fat fed mice 
Based on the data obtained in vitro and in lean mice, [D-Ser2]palmitoyl-paddlefish 
was selected for longer-term studies. Twice-daily administration of the peptide to high-fat fed 
mice resulted in a significant (P < 0.05 - P < 0.001) reduction of food intake starting from day 
13 onwards when compared with high-fat control animals (Fig. 4A). Peptide treatment also 
led to a reduction in body weight from day 18 onwards when compared with control mice 
(Fig. 4B). Administration of the paddlefish glucagon analogue and liraglutide resulted in a 
significant (P < 0.001) decrease in body weight and in the integrated blood glucose 
concentration (Fig. 4C and E) compared with high-fat fed control mice. A reduction of non-
fasting insulin concentrations (P < 0.05) on days 10 and 16 was observed for liraglutide and 
[D-Ser2]palmitoyl-paddlefish glucagon respectably (Fig. 4F).  
 
3.9. Effects of 21-day administration [D-Ser2]palmitoyl paddlefish glucagon on glucose 
tolerance, insulin sensitivity and insulin resistance in high-fat fed mice 
 
Following 21-day treatment with [D-Ser2]palmitoyl-paddlefish glucagon, a significant 
(P < 0.05 - P < 0.001) reduction in blood glucose concentration was observed at the 15 - 120 
min time points after i.p. injection of glucose. This translated to a significant reduction (P < 
0.001) in integrated blood glucose concentration (Fig. 5A). Glucose-stimulated insulin 
concentrations were significantly (P < 0.05 - P < 0.001) increased at 15 - 60 min for the 
group treated with the analogue and the integrated response of insulin release was also 
significantly (P < 0.001) increased (Fig. 5B). [D-Ser2]-palmitoyl paddlefish glucagon 
treatment resulted in significantly (P < 0.05) greater stimulation of insulin release compared 
with liraglutide treatment. In a second series of experiments involving oral glucose 
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administration, there was a significant (P < 0.05) reduction in glucose concentrations at 60, 
90 and 120 min together with significantly (P < 0.05) lowered integrated response the group 
receiving [D-Ser2]palmitoyl-paddlefish glucagon in compared with the control group (Fig. 
5C). Concomitant with the lower blood glucose levels, the concentration of plasma insulin 
was significantly (P < 0.05) greater at 15 min in the group treated with the analogue and the 
integrated insulin responses were significantly (P < 0.05) greater compared with high-fat fed 
control mice (Fig. 5D). 
No significant differences in blood glucose concentrations were observed in the three 
groups after administration of exogenous insulin (Fig. 5E). However, HOMA-IR values were 
significantly greater and HOMA-β values significantly less in the mice receiving either 
liraglutide or the paddlefish glucagon analogue demonstrating that long-term administration 
of the peptides decreased insulin resistance and increased β-cell function compared with 
high-fat fed control mice (Fig. 5F). 
3.10 Effects of 21-day administration [D-Ser2]palmitoyl-paddlefish glucagon on plasma 
glucagon, amylase and alanine aminotransferase activities, blood lipid profile and body mass 
in high-fat fed mice. 
Analysis of plasma after 21-day treatment showed that amylase activity was 
significantly (P < 0.05) elevated (Fig. 6B), and plasma alanine aminotransferase activity was 
significantly (P < 0.05 and P < 0.001) reduced (Fig. 6C) in the peptide-treated groups 
compared with control mice. Plasma glucagon concentrations were not significantly different 
between the groups (Fig. 6A).   
The  plasma lipid profile revealed significant (P < 0.05) reductions in total cholesterol 
and triglyceride concentrations in the group treated with [D-Ser2]palmitoyl-paddlefish 
glucagon when compared with control mice (Figs. 6D and 6E). LDL-cholesterol and HDL-
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cholesterol concentrations were not significantly different between the groups (Figs. 6F and 
6G).  A significant (P < 0.05 - P < 0.01) reduction in fat mass and % body fat was also 
observed in the peptide treatment groups (Figs. 6H and 6I). 
 
3.11. Effects of 21-day administration [D-Ser2]palmitoyl-paddlefish glucagon on pancreatic 
insulin and glucagon content and islet histology in high-fat fed mice 
 
Pancreatic glucagon content in [D-Ser2]palmitoyl-paddlefish glucagon- and 
liraglutide-treated mice was not significantly different compared with high-fat fed control 
animals (Fig. 7B). In contrast, pancreatic insulin content was significantly reduced in both 
treated groups compared to control (Fig. 7A). No appreciable change in islet morphology was 
noted between the liraglutide-treated and control groups (Figs. 7C - 7G). In the group treated 
with [D-Ser2]palmitoyl-paddlefish glucagon there was a significant reduction in α-cell area 
(P < 0.05) (Fig. 7F), as well as a significant (P < 0.05) increase in the number of small (< 
10,000 μm2) islets compared to the control group (Fig. 7G). 
 
3.12. Effects of 21-day administration of [D-Ser2]palmitoyl-paddlefish glucagon on ex-vivo 
insulin secretion from isolated mouse islets and islet gene expression in high-fat fed mice 
 
Islets isolated from high-fat fed mice showed weak insulin secretory responses to 
stimulatory concentrations of glucose, alanine, arginine, potassium chloride, human GLP-1 
and GIP that were improved by 21-day treatment with liraglutide and paddlefish glucagon 
analogue (Fig. 8A). Treatment with both the paddlefish glucagon analogue and liraglutide 
significantly (P  <  0.05) reduced the islet expression of Ins1 (mouse insulin 1) (Fig. 8B) and 
increased the expression of Slc2a2 (glucose transporter 2; GLUT2) (Fig. 8D), Glp1r (Fig. 8E) 
21 
 
and Gcgr (Fig. 8F) compared with control mice but only the paddlefish peptide upregulated 
Gipr expression  (Fig. 8G). 
 
4.  Discussion 
 
This study has extended previous investigations for the design of long-acting anti-
diabetic agents exploiting the structures of proglucagon-derived peptides from 
phylogenetically ancient fish (O’Harte et al., 2016b; Graham et al., 2020) by development 
of a peptidase-resistant analogues of paddlefish and lamprey glucagons.  Both [D-
Ser2]palmitoyl-paddlefish glucagon and [D-Ser2]palmitoyl-lamprey glucagon displayed 
increased resistance to degradation by DPP-IV compared with the native peptide (Table 2)   
DPP-IV converts human glucagon into inactive fragments (Pospisilik et al., 2001) and is 
important in terminating the action of the peptides in vivo (Deacon 2018). The additional 
modification involving the attachment of a fatty acid to the Lys30 residue of the peptide 
promotes binding to albumin and delays renal clearance (Son et al., 2009; Kerr et al., 
2010). This modification has been used in the design of the long-acting incretin, liraglutide 
which has a half-life of 11-15 hours (Wajcberg and Amarah, 2010). Both analogues 
stimulated cAMP production in CHL cells transfected with GLP1R as well as in HEK293 
cells transfected with GCGR (Figs. 1E and 1F) and their insulinotropic properties were 
attenuated in INS-1 cells lacking Glp1r and Gcgr (Figs. 2B and 2C) demonstrating that the 
modifications to the naturally occurring peptides have not abolished their dual-agonist 
properties.   
Paddlefish glucagon contains the segments Glu15-Glu16 and Glu24-Trp25-Leu26-Lys27-
Asn28-Gly29 in common with long-acting GLP1R agonist, exendin-4 leading to the 
suggestion that it represents a naturally occurring hybrid glucagon/exendin-4 molecule 
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(Graham et al., 2018a). The modifications to the peptide resulted in an analogue that was 
equally effective in stimulating insulin release from BRIN-BD11 clonal β-cells but was 10-
fold more potent (Table 2) and also increased the rate of insulin release from isolated 
mouse islets at a concentration of 10 nM (Fig 1D). In contrast, the modified lamprey 
glucagon showed reduced effectiveness in stimulating insulin release from BRIN-BD11 
cells (Table 2) and did not produce a significant response in isolated mouse islets at a 
concentration of 1 µM (Fig. 1C). This marked difference in properties may be a 
consequence of the fact that the palmitate residue is attached to the C-terminal amino acid 
in the lamprey peptide. The site of attachment is important in determining the activities of  
acylated analogues of lamprey and paddlefish GLP-1 (Graham et al., 2020)  and structure-
activity studies involving human GLP-1 showed that the addition of a fatty acid and γ-
glutamyl linker at certain sites in the molecule resulted in up to a 70-fold reduction in potency 
(Knudsen et al. 2000; Madsen et al. 2007). However, both analogues at a concentration of 10 
nM stimulated proliferation of BRIN-BD11 cells (Fig. 2E) but only the paddlefish analogue 
protected the cells against cytokine-induced apoptosis (Fig. 2F).   
In studies with overnight-fasted lean mice, administration of the paddlefish glucagon 
analogue significantly lowered blood glucose concentrations and increased circulating insulin 
concentrations even when injected 4 h before an ip glucose load (Figs. 3E and 3F; 
Supplementary Figure 2). The peptide was as effective as exendin-4 whereas human GLP-1 
and underivatized paddlefish glucagon were ineffective under these conditions.  In studies 
with high-fat fed mice injected twice-daily for 21 days with either the paddlefish glucagon 
analogue or liraglutide, animals treated with the paddlefish analogue were associated with a 
significant decrease in non-fasting blood glucose, plasma insulin and pancreatic insulin 
content (Fig. 4). Moreover, glycaemic responses to intraperitoneal and oral glucose loads 
were improved which correlated with beneficial effects upon insulin resistance and β-cell 
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function (Fig. 4). These improvements in glycaemic control and insulin resistance will 
decrease the functional demand for insulin and so permit beneficial β-cell rest (Pathak et al., 
2015).  
In addition to positive effects on glucose homeostasis, the paddlefish glucagon 
analogue significantly suppressed food intake and body weight in these animals. This finding 
is consistent with the DEXA scan results showing a reduction in adipose tissue which would 
also be expected to contribute to the improvements of insulin sensitivity and metabolic 
control. Consumption of a diet high in fact induces dyslipidemia with increased 
concentrations of plasma cholesterol, low levels of HDL cholesterol and increased levels of 
triglycerides (Ipsen et al., 2016). Treatment with the paddlefish glucagon analogue reduced 
total cholesterol and decreased circulating triglycerides in high-fat fed mice (Fig. 6). In the 
present study, liraglutide failed to improve the lipid profile. However, other investigations 
have shown a decrease in triglyceride levels in mice treated once daily with liraglutide 
(Millar et al., 2017; O’Harte et al., 2018). Feeding a high-fat diet also results in 
steatohepatitis and inflammasome activation (Ganz et al., 2014; Stephenson et al., 2018). 
Treatment with the analogue reduced plasma aminotransferase activity (Fig. 6), which 
suggests that the peptide, like liraglutide, may exercise a protective action against liver 
damage. On the other hand, administration of liraglutide and the paddlefish glucagon 
analogue modestly increased levels of circulating amylase which may suggest a possible risk 
of pancreatitis (Gier et al., 2012). Indeed, there has been concern regarding possible adverse 
effects of GLP1R agonist drugs on pancreatic and thyroid tissue since animal studies and 
analyses of drug databases suggest a possible link between these medications and 
pancreatitis, pancreatic cancer, and thyroid cancer (Filippatos et al., 2014). However, meta-
analyses (Alves et al., 2012) and LEADER randomised trials (Steinberg et al., 2017) failed to 
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confirm that the increase of serum amylase caused by GLP-1 mimetics is implicated in these 
conditions.  
 A high-fat diet leads to development of insulin resistance with a concomitant 
elevation in blood glucose levels arising from reduced insulin-mediated glucose uptake by the 
peripheral tissues and increased hepatic glucose production. In response, β-cells compensate 
by releasing more insulin and there is an increase in β-cell mass via proliferation (Golson et 
al., 2010; Sachdeva and Stoffers, 2009; Vasu et al., 2014). The histological findings reveal 
that treatment with the paddlefish glucagon analogue significantly reduced α-cell area 
compared to high-fat fed controls. Although not significant, the β-cell area was also 
decreased in this group which correlated with a higher number of smaller-sized islets. 
Consistent with this observation, although no change in plasma glucagon concentrations were 
detected, islet insulin and glucagon content were decreased in this group. This finding may 
indicate a restoration of α-cell function and ability to respond to glucose similar to the 
observed beneficial action of GLP-1 (Vilsboll, 2009; Hare et al., 2010). In contrast, there 
were no significant changes in any histological parameters in the liraglutide treatment group. 
A major challenge in diabetes research is understanding the multiple effects of 
glucose on β-cells in molecular terms by revealing the sites of dysregulation in gene 
expression caused by chronically elevated glucose concentrations (Schuit et al., 2002). 
Effective drugs that will reverse these molecular abnormalities are clearly required.  Insulin 
gene (Ins1) transcription, which is up-regulated by an increase in blood glucose levels 
(Mosley et al., 2004), was decreased in mice treated with liraglutide and the paddlefish 
glucagon analogue compared to high-fat fed controls (Fig 8). This may be a consequence of 
the decreased circulating glucose levels in the treatment groups. Moreover, expression of 
Slc2a2 gene encoding GLUT2, which regulates the entry of glucose into the β-cell, was 
significantly higher in the treatment groups. Decreased expression of Slc2a2 is a hallmark of 
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β-cell glucose unresponsiveness (Thorens, 2015) so that the increased expression observed in 
this study may be responsible for the enhanced glucose sensitivity which in turn is beneficial 
for the preservation of insulin secretion by the pancreatic β- cells (Laukkanen et al., 2005). 
Stimulation of insulin release by GLP-1 and GIP is impaired in T2DM which correlates with 
the decreased expression GLP1R and GIPR receptors in diabetic subjects (Xu et al., 2007). 
Both liraglutide and the paddlefish glucagon analogue had a positive impact on the 
expression of Glp1r in high-fat fed mice compared with controls but only treatment with the 
paddlefish glucagon analogue resulted in a higher expression of Gipr despite the fact that 
treatment with both peptides enhanced the insulinotropic effects of GLP-1 and GIP in 
isolated islets (Fig. 8A). A higher expression of the Gcgr gene was observed in both peptide 
treatment groups. Previous studies suggest that glucagon may play a crucial role in pancreatic 
β-cell growth and differentiation. Gcgr-/- mice were shown to have a decreased percentage of 
β-cells per islet compared to control animals and less severe hyperglycaemia was observed in 
RIP-Gcgr mice overexpressing the glucagon receptor in the pancreas (Gelling et al., 2009). 
To conclude, [D-Ser2]palmitoyl-paddlefish glucagon is a potent dual-acting agonist 
that activates both GLP-1 and glucagon receptors and exhibits anti-hyperglycaemic, 
insulinotropic and proliferative effects as well as enhanced stability in plasma. 
Administration of the analogue had beneficial effects on food intake, body weight, glucose 
tolerance, insulin resistance, lipid profile, islet morphology, islet gene expression and β-cell 
function in high-fat fed mice with actions similar or superior to those of liraglutide. 
Exploitation of the structures of proglucagon-derived peptides from phylogenetically ancient 
fish, such as the paddlefish, may lead to the development new improved agents for treatment 
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Legends to Figures 
Fig. 1. (A) Stability of the fish glucagon analogues after 4 h incubation with plasma. Effects 
of (B) [D-Ser2]palmitoyl-lamprey glucagon and (C) [D-Ser2]palmitoyl-paddlefish glucagon  
on insulin release from BRIN-BD11 cells. (D) Effects of fish glucagon peptides (10-8 and 10-6 
M) on insulin release from isolated mouse pancreatic islets. Effects of fish glucagon peptides  
(10-8 and 10-6 M) on cAMP production in (E) GLP1R-transfected CHL cells and (F) GCGR-
transfected HEK293 cells. Values are mean ± S.E.M. In panels B and C, n = 8. *P < 0.05, 
**P < 0.01, ***P < 0.001 compared to 5.6 mM glucose alone. In panel D, n = 4; *P < 0.05, 
**P < 0.01, ***P < 0.001 compared to 16.7mM glucose alone. In panels E and F, n = 3. *P < 
0.05, ** P < 0.01 and ***p < 0.001 compared with 5.6 glucose alone. Δ P< 0.05, ΔΔP < 0.01 
and ΔΔΔP < 0.001 compared with the corresponding effects of GLP-1 or glucagon. 
 
Fig. 2. Effects of  [D-Ser2]palmitoyl-lamprey glucagon and [D-Ser2]palmitoyl-paddlefish 
glucagon (10-8 and 10-6 M) on the rate of insulin release from (A) wild-type INS-1 cells, (B) 
Glp1r KO INS-1 cells, (C) Gcgr KO INS-1 cells and (D) Gipr KO cells. (E) Effects of the 
fish glucagon analogues and human GLP-1 (10-8 and 10-6 M) on proliferation of BRIN-BD11 
cells. (F)  Effects of the fish glucagon analogues and human GLP-1 (10-8 and 10-6 M) on the 
protection of BRIN-BD11 cells against cytokine-induced apoptosis.  Values are 
mean ± S.E.M. In panels A-D,  n = 8;  *P < 0.05, **P < 0.01 and ***P < 0.001 compared 
with 5.6 mM glucose alone; ΔP < 0.05, ΔΔP < 0.01, ΔΔΔP < 0.001 compared with effects in 
wild-type INS-1 cells. In panel E, n = 3 ***P < 0.001 compared with control cultures. In 





Fig. 3. Effects of administration of lamprey glucagon, paddlefish glucagon, [D-
Ser2]palmitoyl-lamprey glucagon and [D-Ser2]palmitoyl-paddlefish glucagon (25 nmol/kg)  
 on (A) blood glucose and (B) plasma insulin concentrations in lean mice after simultaneous 
ip injection of glucose (18 mmol/kg). The integrated responses (area under the curve, AUC) 
are shown in panels C and D. The integrated responses when administered 4 h before 
intraperitoneal injection of glucose (18 mmol/kg) are shown in panels E and F. The values are 
mean ± S.E.M. for n = 6. *P < 0.05, **P < 0.01 and ***P < 0.001 compared with glucose 
alone; Δ P < 0.05, ΔΔ P < 0.01, ΔΔΔP < 0.01 compared with human GLP-1. 
 
Fig. 4. Effects of 21-day administration of [D-Ser2]palmitoyl-paddlefish glucagon on (A) 
food intake, (B) body weight, (C) % change in body weight, (D) non-fasting blood glucose 
concentrations, (E), % change in blood glucose concentrations and (F) plasma insulin 
concentrations in high-fat fed mice. The black horizontal bar represents the treatment period. 
Values represent mean ± S.E.M. for 8 mice. *P < 0.05, **P < 0.01 and ***P < 0.001 
compared with high-fat fed control mice; Δ P < 0.05, ΔΔP < 0.01 compared with liraglutide. 
 
Fig. 5. Effects of [D-Ser2]palmitoyl-paddlefish glucagon an (A) blood glucose concentration 
and (B) plasma insulin concentration after ip glucose administration, (C) blood glucose 
concentration and (D) plasma insulin concentration after oral glucose administration (E) 
insulin sensitivity and (F) HOMA-β and HOMA-IR in high-fat fed mice. The parameters 
were measured on day 21 following twice-daily treatment with saline vehicle, liraglutide (25 
nmol/kg) or [D-Ser2]palmitoyl-paddlefish glucagon (25 nmol/kg). Values represent mean ± 





Fig. 6. Effects of 21-day intraperitoneal administration of D-Ser2]palmitoyl-paddlefish 
glucagon on (A) plasma glucagon concentrations, (B) amylase and (C) alanine 
aminotransferase activities (D), cholesterol (E) triglyceride, (F) HDL, (G) LDL 
concentrations, (H) whole body fat mass and (I) % fat mass in high-fat fed mice. Parameters 
were measured on day 21 following twice-daily treatment with 0.9% NaCl, liraglutide (25 
nmol/kg) or the paddlefish glucagon analogue (25 nmol/kg). Data are expressed as mean ± 
S.E.M.; n = 4. *P < 0.05, ** P < 0.01, *** P < 0.001 compared with saline control. 
Fig. 7. Effects of 21-day administration [D-Ser2]-palmitoyl paddlefish glucagon and 
liraglutide on (A) pancreatic insulin content, (B) pancreatic glucagon content (C) number of 
islets, (D) islet area, (E) β-cell area, (F) α-cell area, and (G) islet size distribution (% of total 
area) in high-fat fed mice. Parameters were measured on day 21 following twice-daily 
treatment with peptides (25 nmol/kg). ***P < 0.001 compared to high-fat fed control 
animals. Approximately 50 islets per mouse were analysed using Cell^F analysis software.  
Fig. 8. (A)  Effects of established insulin secretogogues on insulin secretion from isolated 
mouse islets from high-fat fed mice after treatment with D-Ser2]-palmitoyl paddlefish 
glucagon or liraglutide. Effects of 21-day treatment with peptides on islet gene expression of 
(B) Ins1, (C) Gck, (D) Slc2α2, (E) Gcgr, (F) Glp1r, and (G) Gipr. Data were normalised to β-
actin (Actb) gene expression. Values are means ± S.E.M. for n = 3. *P < 0.05, ** P< 0.01 and 







Table 1.  Primary structures and molecular masses of the glucagon-related peptides 
investigated in this study. 
 






Human glucagon HSQGTFTSDYSKYLDSRRAQDFVQWLMNT 3482.8 3484.4 
Lamprey glucagon HSEGTFTSDYSKYLENKQAKDFVRWLMNA 3466.9 3466.5 



























Table 2. Degradation of fish and human glucagon-related peptides after 4 h incubation with 
dipeptidyl peptidase IV (DPP-IV) and plasma 
 
Peptide % degraded  







 cleavage site 
Lamprey glucagon 42 ND 3243.1 Ser2-Glu3 
Paddlefish glucagon 14 ND 3429.7 Ser2-Gln3 
[D-Ser2]palmitoyl- 
lamprey glucagon 
0 0 NA NA 
[D-Ser2]palmitoyl-
paddlefish glucagon  
0 0 NA NA 
Human glucagon 24 35 3259.5 Ser2-Gln3 
 






















Table 3. Effects of fish and human glucagon-related peptides on the rate of insulin release 





Effect at 3µM 
 (ng/106 cells/20min) 
5.6 mM glucose    - 1.0 ± 0.02 
Lamprey glucagon+ 3b 3.3 ± 0.2c 
Paddlefish glucagon+ 0.1a 3.6 ± 0.2c 
[D-Ser2]palmitoyl-lamprey glucagon 0.3a 2.4 ± 0.1c 
[D-Ser2]palmitoyl-paddlefish glucagon 0.01a 3.3 ± 0.2c 
Human glucagon 100a 2.7 ± 0.2c 
 
The threshold concentration is the minimum concentration of the peptide producing a 
significant (p < 0.05) increase in the rate of insulin release. The values are mean ± S.E.M. for  
n = 8. aP < 0.05, bP < 0.01, cP < 0.001 compared to 5.6 mM glucose alone. +Data taken from 







































































Supplementary Fig. 1. Effects of lamprey glucagon, [D-Ser2]palmitoyl-lamprey glucagon, 
paddlefish glucagon, [D-Ser2]palmitoyl-paddlefish glucagon and exendin-4 (25 nmol/kg) on 
circulating (A) glucose and (C) insulin concentrations in lean mice administered  2 h  before 
i.p. injection of a glucose load (18 mmol/kg). The respective integrated responses (area under 
the curve, AUC) are shown in panels B and D. The values are mean ± SEM for n = 6. 
*P<0.05 **P<0.01 and ***P<0.001 compared to glucose alone; Δ P<0.05, ΔΔ P<0.01 and ΔΔΔ 





Supplementary Fig. 2. Effects of [D-Ser2]palmitoyl-lamprey glucagon, paddlefish glucagon,  
[D-Ser2]palmitoyl-paddlefish glucagon and exendin-4 (25 nmol/kg) on circulating (A) 
glucose and (C) insulin concentrations in lean mice administered 4 h  before i.p. injection of a 
glucose load (18 mmol/kg). The respective integrated responses (area under the curve, AUC) 
are shown in panels B and D. The values are mean ± SEM for n = 6. *P<0.05 **P<0.01 and 




Supplementary Fig. 3. Effects of (A) lamprey glucagon and [D-Ser2]palmitoyl-lamprey 
glucagon and (B) paddlefish glucagon and [D-Ser2]palmitoyl-paddlefish glucagon on 
cumulative food intake over 3 h feeding in 12 h fasted lean mice. Cumulative food intake was 
measured after intraperitoneal administration of fish peptides and exendin-4 (25 nmol/kg). 
The values are mean ± SEM for n = 8. *P < 0.05, **P < 0.01 and ***P < 0.001 compared 
with control mice treated with saline only. 
